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Abstract
QUESTIONS UNDER STUDY: Monitoring of antimicrobial resistance is a key component of antibiotic
stewardship programs. In 2007, a significantly higher resistance rate of Escherichia coli to ciprofloxacin
was found at the Department of Urology, University Hospital Zurich, Switzerland, when compared to
other hospital units. Thus, we aimed to determine the risk factors for this increased fluoroquinolone
resistance in outpatients and inpatients with urinary tract infection (UTI) or colonisation with E. coli.
METHODS: We performed a cross sectional study including 275 patients of the Department of Urology
in whom E. coli was isolated from urine or blood cultures between 01.01.2006 and 31.08.2007. Clinical
data were collected from patients' records using a structured questionnaire. Multivariable analysis was
performed for the detection of risk factors. RESULTS: Ciprofloxacin-resistant E. coli was detected in
22% of patients. Risk factors for ciprofloxacin-resistant E. coli included prior use of fluoroquinolones
(odds ratio [OR] (95% confidence intervals): 2.24 (1.08-4.62), p = 0.030), prior urinary tract
catheterisation (OR: 2.41 (1.02-5.67), p = 0.044) and recurrent UTIs (OR: 2.26 (1.07-4.78), p = 0.032).
60.8% of all prescriptions in urinary tract infections were for fluoroquinolones, and this antibiotic class
was the empiric antibiotic regimen of choice in 72.5% of all acute, uncomplicated, urinary tract
infections. CONCLUSIONS: The increasing prevalence of ciprofloxacin-resistant E. coli makes empiric
therapy in UTIs with this agent questionable, especially in patients with one or several of the above
mentioned risk factors. Due to the increasing resistance rate, continuous surveillance and susceptibility
testing in individual patients, particularly with complicated UTIs, is indispensable for adequate therapy
Methods: We performed a cross sectional study including 275 patients of the Department of Urology in
whom E. coli was isolated from urine or blood cultures between 01.01.2006 and 31.08.2007. Clinical
data were collected from patients' records using a structured questionnaire. Multivariable analysis was
performed for the detection of risk factors. Results: Ciprofloxacin-resistant E. coli was detected in 22%
of patients. Risk factors for ciprofloxacin-resistant E. coli included prior use of fluoroquinolones (odds
ratio [OR] (95% confidence intervals): 2.24 (1.08-4.62), p = 0.030), prior urinary tract catheterisation
(OR: 2.41 (1.02-5.67), p = 0.044) and recurrent UTIs (OR: 2.26 (1.07-4.78), p = 0.032). 60.8% of all
prescriptions in urinary tract infections were for fluoroquinolones, and this antibiotic class was the
empiric antibiotic regimen of choice in 72.5% of all acute, uncomplicated, urinary tract infections.
Conclusions: The increasing prevalence of ciprofloxacin-resistant E. coli makes empiric therapy in UTIs
with this agent questionable, especially in patients with one or several of the above mentioned risk
factors. Due to the increasing resistance rate, continuous surveillance and susceptibility testing in
individual patients, particularly with complicated UTIs, is indispensable for adequate therapy.
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Summary
Questions under study: Monitoring of antimicrobial resistance is a key component of antibiotic stewardship programs. In
2007, a significantly higher resistance rate of Escherichia coli to ciprofloxacin was found at the Department of Urology,
University Hospital Zurich, Switzerland, when compared to other hospital units. Thus, we aimed to determine the risk
factors for this increased fluoroquinolone resistance in outpatients and inpatients with urinary tract infection (UTI) or
colonisation with E. coli.
Methods: We performed a cross sectional study including 275 patients of the Department of Urology in whom E. coli
was isolated from urine or blood cultures between 01.01.2006 and 31.08.2007. Clinical data were collected from patients’
records using a structured questionnaire. Multivariable analysis was performed for the detection of risk factors.
Results: Ciprofloxacin-resistant E. coli was detected in 22% of patients. Risk factors for ciprofloxacin-resistant E. coli
included prior use of fluoroquinolones (odds ratio [OR] (95% confidence intervals): 2.24 (1.08–4.62), p = 0.030), prior
urinary tract catheterisation (OR: 2.41 (1.02–5.67), p = 0.044) and recurrent UTIs (OR: 2.26 (1.07–4.78), p = 0.032).
60.8% of all prescriptions in urinary tract infections were for fluoroquinolones, and this antibiotic class was the empiric
antibiotic regimen of choice in 72.5% of all acute, uncomplicated, urinary tract infections.
Conclusions: The increasing prevalence of ciprofloxacin-resistant E. coli makes empiric therapy in UTIs with this agent
questionable, especially in patients with one or several of the above mentioned risk factors. Due to the increasing
resistance rate, continuous surveillance and susceptibility testing in individual patients, particularly with complicated UTIs,
is indispensable for adequate therapy.
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Introduction
Urinary tract infections (UTIs) are common infections among inpatients and outpatients, ranking second only to
respiratory infections, and thus, are a frequent cause for prescription of antibiotics [1]. Common pathogens causing
uncomplicated UTIs are Escherichia coli (75–90% of UTIs) and Staphylococcus saprophyticus (5–15% of UTIs, particularly
in younger women). Occasionally, Proteus mirabilis, Klebsiella spp. or enterococci are isolated from urine samples [2].
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Fluoroquinolones are often prescribed empirically and as a first choice in patients with UTIs, achieving high concentrations
in urine and showing a broad antibacterial spectrum. In 2000, fluoroquinolones were prescribed for treatment of acute,
uncomplicated UTIs in Switzerland in 64% of cases [3]. Knowledge of the most frequent microorganisms and their
susceptibility pattern are the basis for empirical antimicrobial therapy, especially in UTIs, as susceptibility testing is often
not performed in the community setting. Unfortunately, this diagnostic and therapeutic approach is becoming more and
more limited because of increasing resistance to commonly used antimicrobial drugs.
Across Europe, levels of antibiotic consumption show great variations [4], with the use of fluoroquinolones being
highest in Portugal and Spain. As the emergence of resistance is associated with high antibiotic consumption [5, 6], it is
not surprising that resistance to ciprofloxacin in E. coli shows great geographical variations, too, reaching high levels in
southern Europe and low levels in northern European countries [6–8]. In addition to attentive monitoring of resistance
patterns, the identification of risk factors for infections with resistant strains may contribute to improved empirical
treatment. Factors associated with resistance to ciprofloxacin in E. coli reported in previous studies are urinary tract
abnormalities, older age, previous antimicrobial therapy (especially quionolone therapy), urinary catheterisation,
recurrent UTIs, male gender and presence of complicated UTI [9–13]. In our hospital, resistance rates of E. coli to
ciprofloxacin in inpatients range from as low as 4.9% to as high as 35.5% across hospital units, and resistance rates at
the Department of Urology have been shown to be significantly higher compared to other hospital units [14]. Resistance
rates of in- and outpatients at our hospital ranged from 0 to 40% in 2008 [unpublished internal report].
The goals of this study were (i) to determine resistance rates in outpatients and inpatients with UTIs, (ii) to assess
prescribers’ choices for empirical antibiotic therapy, and (iii) to identify risk factors for infections due to ciprofloxacin-
resistant E. coli in patients at the Department of Urology of the University Hospital Zurich, Switzerland.
Methods
Setting
The University Hospital in Zurich, Switzerland, is an 861 beds tertiary care teaching hospital. 36 beds are assigned to the
Department of Urology. 1722 patients were admitted in 2006, accounting for 10412 bed-days (day of admission and day
of discharge counted together as one bed-day) and a mean length of stay of 6.0 days. In the same year, 6514 patients
were treated in the outpatient unit.
Patients
We performed a cross sectional study at the Department of Urology. All adult inpatients and outpatients were included in
whom E. coli was isolated from clinical urinary samples or blood cultures (in case of clinical symptoms suggestive of
urinary tract infection but negative urinary culture) in the study period from January 1, 2006 to August 31, 2007. Most of
the in- and outpatients presenting with complicated urinary tract infections to the University Hospital Zurich are treated at
the Department of Urology, except kidney transplant recipients. At our hospital, acute, uncomplicated urinary tract
infections and women with acute, uncomplicated pyelonephritis are treated at the Department of Urology, the Department
of Gynecology and Obstetrics, and at the Medical Emergency Department.
All specimens were tested in a central clinical microbiology laboratory (Institute of Medical Microbiology, University of
Zurich). Bacteria were isolated from urine and blood cultures according to standard methods [15]. Antimicrobial
susceptibility testing and screening for extended spectrum beta-lactamase (ESBL) was performed according to the Clinical
and Laboratory Standards Institute (CLSI) [16]. Briefly, in the disk diffusion test, ciprofloxacin zone diameters of <15 mm
and of >21 mm were considered resistant and susceptible, respectively; zones of 16–20 mm were considered as
intermediately susceptible but were categorised as non-susceptible. Some strains were tested by a commercial
microdilution test (Vitek2, BioMérieux, Marcy L’Étoile, France); minimal inhibitory concentrations (MIC) of ciprofloxacin of
<1 mg/L and of >4 mg/L were considered susceptible and resistant, respectively; an MIC of 2 mg/L was intermediately
susceptible but was categorised as non-susceptible. The screening test for ESBL was an inhibition zone of <22 mm
against ceftazidime or of <27 mm against cefotaxime. Any synergy between amoxicillin/clavulanic acid and ceftazidime or
cefepime (double disk method), or between piperacillin/tazobactam and cefotaxime in the disk diffusion test was also an
indication for a confirmation test by Etest according to the prescription of the manufacturer (AB Biodisk, Solna, Sweden);
a greater than twofold concentration decrease in an MIC for ceftazidime or cefepime, or for cefotaxime tested in
combination with clavulanic acid versus its MIC when tested alone was confirmatory for ESBL. In accordance with the
CLSI guidelines, all ESBL-producing E. coli strains were classified as resistant to all penicillins, cephalosporins and
aztreonam regardless of the MICs determined for these drugs [16].
Demographic and clinical information of both in- and outpatients was collected from each patient by chart review using
a structured questionnaire.
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Definitions
Bacterial counts with 104 colony forming units or more per millilitre of urine in asymptomatic patients were considered to
represent asymptomatic bacteriuria. Acute, uncomplicated urinary tract infection was defined as symptomatic cystitis,
characterised by frequency, dysuria, suprapubic pain and urgency in women with a normal urogenital tract. In men,
symptomatic urinary tract infections were classified as complicated. Acute, uncomplicated pyelonephritis was defined as a
parenchymatous infection of the kidney in women with normal urogenital tract who presented with flank pain and often
fever. Complicated urinary tract infection was defined as symptomatic cystitis or pyelonephritis in men or women with
functional or structural abnormalities of the urogenital tract. Any detection of E. coli in blood culture samples was
considered significant bacteremia. Infections were considered nosocomial if the patient was hospitalised in an acute care
centre for >48 hours prior to sample collection. One antibiotic course was defined as administration of at least one dose
of any antibacterial agent. A time interval of >24 hours between the administration of two doses was defined to separate
one course from another, unless certain conditions (e.g. renal insufficiency) justified a dose interval of >24 hours. The
variable ‘recurrent UTIs’ was recorded according to the available information from patient history without definition of a
threshold.
Calculation of the Chronic Disease Score was performed according to McGregor et al. [17].
Statistical analysis
We used Stata (Version 10, StataCorp, College Station, Texas) for statistical analyses. Differences in group proportions
were assessed by the Chi-square or Fisher’s exact test, and differences in medians were calculated with the Wilcoxon
rank-sum test. Logistic regression analysis was performed to identify risk factors for acquisition of fluoroquinolone-
resistant E. coli. In multivariable analysis, male gender and all variables revealing a p value <0.2 in univariable analysis
were included. A p value <0.05 was considered statistically significant.
Ethics approval
The study was approved by the local ethics committee.
Results
Patients and antibiotic prescriptions
275 patients were enrolled and a total of 345 urinary or blood culture samples were analysed. Patients’ characteristics,
clinical presentation and microbiological findings are summarised in table 1. The median age (interquartile range (IQR)) of
the 151 (55%) women and the 124 (45%) men was 56.8 (51.9–60.4) years. Of the population studied, 178 (65%)
subjects were treated as outpatients and 97 (35%) as inpatients. The most common diagnosis was acute, uncomplicated
UTI (80 (29%) patients), followed by complicated UTI (69 (25%) patients). Ciprofloxacin-resistant E. coli was isolated in
61 patients, representing 36% of all inpatients and 15% of outpatients.
174 out of 286 (60.8%) initial antibiotic prescriptions were for fluoroquinolones, 13% were for penicillins and 7% were
for sulfamethoxazole-trimethoprim. Fluoroquinolones were the empiric antibiotic therapy of choice in 72.5% (58/80) of all
acute, uncomplicated urinary tract infections, in 76.5% (13/17) of all episodes of acute, uncomplicated pyelonephritis and
in 65.0% (52/80) of all complicated urinary tract infections. Penicillins accounted for 10.0%, 17.6% and 16.3%,
respectively, and sulfamethoxazole-trimethoprim accounted for 12.5%, 5.9% and 8.8%, respectively.
Predictors of ciprofloxacin-resistant E. coli
The characteristics of patients with ciprofloxacin-resistant strains were compared with those of patients with a
ciprofloxacin-susceptible strain (table 2). Significant predictors of ciprofloxacin-resistant E. coli in univariable analysis
were inpatient status, recurrent UTIs, urolithiasis, foreign material (e.g. pigtail catheter) in the upper urinary tract,
urinary catheter, prior use of fluoroquinolones, prior use of any antibiotics and prior treatment in the Department of
Urology. To identify independent risk factors, a multivariable analysis was performed. Thereby, fluoroquinolone use in the
preceding year (odds ratio [OR] (95% confidence intervals [CI]): 2.24 (1.08–4.62), p = 0.030), urinary tract
catheterisation in the preceding year (OR: 2.41 (1.02–5.67), p = 0.044) and recurrent urinary tract infections (OR: 2.26
(1.07–4.78), p = 0.032) were found to be independently associated with infection or colonisation with a ciprofloxacin-
resistant strain.
A further analysis of prior antibiotic use is depicted in table 3. Only one cycle of fluoroquinolone treatment in the
preceding year significantly increased the odds of being infected or colonised with a ciprofloxacin-resistant E. coli strain
(OR: 2.80 (1.51–5.22), p <0.001), whereas one cycle of any antibiotic in the prior 12 months did not (OR: 1.36
(0.73–2.53), p = 0.339). However, the odds were significantly increased when multiple antibiotic cycles were recorded
(OR: 4.40 (2.36–8.20), p <0.001), regardless of the antibiotic class used.
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Antibiotic susceptibility of E. coli resistant and susceptible to ciprofloxacin
The cumulative antibiograms of ciprofloxacin-resistant and ciprofloxacin-susceptible E. coli strains are shown in table 4. Of
the 345 isolates, 94 (27%) were resistant to ciprofloxacin. Compared with susceptible strains, ciprofloxacin-resistant E.
coli strains showed significantly increased resistance rates to all antimicrobials tested, except for piperacillin-tazobactam
and carbapenems (meropenem and imipenem). Among ciprofloxacin-susceptible strains, resistance to ampicillin (28%),
tetracycline (20%) and trimethoprim-sulfamethoxazole (16%) was most prevalent. Ciprofloxacin-resistant strains
produced extended-spectrum beta-lactamases (ESBL) significantly more often than ciprofloxacin-susceptible strains (p
<0.0001).
Table 1
Patient characteristics.
Susceptibility of E. coli to ciprofloxacinCharacteristic
Susceptible, n (%) Resistant, n (%)
p value
Total number of patients 214 (100) 61 (100)
Female 121 (57) 30 (50) 0.312
Male 93 (43) 31 (51) 0.312
Age, median (95% CI) 55.5 (49.2–58.1) 63.8 (54.0–70.0) 0.062
Setting
Outpatients 152 (71) 26 (43) <0.001
Inpatients 62 (29) 35 (57) <0.001
Length of stay, days, median (95%
CI)
4 (4–6) 7 (5–10) 0.094
Chronic Disease Score, median
(95% CI)
4.7 (3–5.5) 3 (3–4) 0.083
Clinical presentation
Asymptomatic bacteriuria 41 (19) 12 (20) 1.000
Asymptomatic bacteriuria with
indwelling catheter
18 (8) 9 (15) 0.148
Acute, uncomplicated urinary tract
infection
74 (35) 6 (10) <0.001
Acute, uncomplicated pyelonephritis 16 (7) 1 (2) 0.132
Complicated urinary tract infection 52 (24) 28 (46) 0.002
Bacteremia 0 (0) 1 (2) 0.222
Other/unclear diagnosis 13 (6) 4 (7) 1.000
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Table 2
Risk factors for urinary tract infections with ciprofloxacin-resistant E. coli.
Susceptibility of E. coli to
ciprofloxacin
Univariable analysis Multivariable logistic regression
analysis
Variable
Susceptible, n
(%)
Resistant, n
(%)
OR (95% CI) p
value
OR (95% CI) p value
Number of patients 214 (100) 61 (100)
Male gender 93 (43) 31 (51) 1.34 (0.76–2.38) 0.309 1.57 (0.77-3.17) 0.212
Age >65 years 78 (36) 29 (48) 1.58 (0.89–2.81) 0.119 1.00 (0.50-2.01) 0.995
In-hospital treatment 62 (29) 35 (57) 3.30 (1.83–5.94) <0.001 1.98 (0.95-4.12) 0.069
Chronic Disease Score >31 31 (50) 16 (46) 0.73 (0.32–1.70) 0.470
Diabetes mellitus 15 (7) 3 (5) 0.69 (0.19–2.45) 0.562
Malignoma, non-urological 4 (2) 1 (2) 0.88 (0.10–7.98) 0.906
Malignoma, urological 18 (8) 10 (16) 2.14 (0.93–4.91) 0.074
Nosocomial infection 4 (2) 1 (2) 0.88 (0.10–7.98) 0.906
Recurrent urinary tract infection 73 (34) 33 (54) 2.28 (1.28–4.05) 0.005 2.26 (1.07–4.78) 0.032
Vesico-ureteral reflux 1 (0) 2 (3) 7.22
(0.64–81.01)
0.109 3.77 (0.28–50.43) 0.316
Benign prostatic hyperplasia2 25 (27) 9 (29) 1.30 (0.58–2.98) 0.521
Urolithiasis 16 (7) 10 (16) 2.43 (1.03–5.67) 0.040 1.72 (0.61–4.85) 0.303
Urologic surgery in last 12 months3 41 (19) 27 (44) 3.35 (1.82–6.16) <0.001
Foreign material in upper urinary tract in
last 12 months3
13 (6) 12 (20) 3.79 (1.63–8.81) 0.002
Urinary catheter in last 12 months 39 (18) 33 (54) 5.29 (2.87–9.75) <0.001 2.41 (1.02–5.67) 0.044
Fluoroquinoloneuse in last 12 months 49 (23) 36 (59) 4.85 (2.66–8.85) <0.001 2.24 (1.08–4.62) 0.030
Use of other antibiotics in last 12
months
56 (26) 31 (51) 2.92 (1.62–5.25) <0.001 1.59 (0.79–3.20) 0.195
Hospitalisation in Department of
Urology in last 12 months
22 (10) 23 (38) 5.28
(2.68–10.43)
<0.001 1.28 (0.50–3.26) 0.607
Corticosteroids or other
immunosuppressants in last 12 months
9 (4) 3 (5) 1.18 (0.31–4.49) 0.810
Renal insufficiency 4 (2) 3 (5) 2.72
(0.59–12.48)
0.199 1.97 (0.32–12.06) 0.464
Kidney transplant recipient 1 (0) 1 (2) 3.55
(0.22–57.60)
0.373
HIV infection 3 (1) 1 (2) 1.17(0.12–11.47) 0.891
1 inpatients, 2 in male patients, 3 these variables have been excluded in the multivariable analysis because of collinearity
Table 3
Antibiotic treatment within the previous 365 days.
Susceptibility of E. coli to ciprofloxacin
Susceptible, n (%) Resistant, n (%)
OR (95% CI) p value
Total number of patients 214 (100) 61 (100)
No prior treatment 130 (61) 14 (23) 0.19 (0.10–0.37) <0.001
Fluoroquinolones
1 cycle 38 (18) 23 (38) 2.80 (1.51–5.22) 0.001
>1 cycle 11 (5) 13 (21) 5.00 (2.15–11.64) <0.001
All antibiotics
1 cycle 51 (24) 19 (31) 1.36 (0.73–2.53) 0.339
>1 cycle 33 (15) 28 (46) 4.40 (2.36–8.20) <0.001
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Table 4
Cumulative antibiograms of 345 E. coli isolates from 275 patients.
Susceptibility of E. coli to ciprofloxacinVariable
Susceptible, n (%) Resistant, n (%)
p value
Ciprofloxacin 251 (100) 94 (100)
Amoxicillin-clavulanate 6 (2) 17 (18) <0.001
Ampicillin 71 (28) 83 (90) <0.001
1st generation Cephalosporins 9 (4) 27 (29) <0.001
Gentamicin 3 (1) 39 (41) <0.001
Piperacillin-tazobactam 5 (2) 4 (4) 0.262
Sulfamethoxazole and trimethoprim 39 (16) 57 (62) <0.001
Tetracycline 50 (20) 66 (72) <0.001
Tobramycin 3 (1) 18 (20) <0.001
Ceftazidime 3 (1) 12 (13) <0.001
Ceftriaxone 1 (0) 12 (13) <0.001
Meropenem 5 (2) 0 (0) 0.329
Imipenem 0 (0) 0 (0) n.a.
Extended-Spectrum Beta-Lactamase
producing strain
1 (0) 10 (11) <0.001
Discussion
The aim of this study was to identify risk factors for colonisation or infection with ciprofloxacin-resistant E. coli in patients
treated at the Department of Urology of the University Hospital Zurich. Our analysis demonstrated that 22% of the
population under study was infected or colonised with ciprofloxacin-resistant E. coli. Recurrent urinary tract infections,
urinary catheterisation within the last 12 months and use of fluoroquinolones in the last 12 months turned out to be
independently associated with ciprofloxacin-resistant strains. Those resistant strains were often also resistant to other
antibiotics, mostly against ampicillin (90%) and tetracyclin (72%). Fluoroquinolones turned out to be the most frequently
prescribed antibiotics for treatment of acute uncomplicated UTI, acute uncomplicated pyelonephritis and complicated UTI.
Our study documents risk factors for UTIs caused by ciprofloxacin-resistant E. coli in patients at a tertiary care urology
centre. The population studied is exceptional in respect to the high prevalence of diseases that facilitate urinary tract
infections, for example urinary tract obstructions, or foreign material in the upper and lower urinary tract. The study has
several limitations. Internal validity may be reduced, as measurement bias might have been introduced by collecting
demographic and medical information by chart review. Charts of outpatients are usually not as detailed as those of
inpatients, probably accounting for systematic deviations in the availability of information. Recall bias might have been
introduced as patients with underlying urinary tract disorders might more appropriately report their antibiotic treatment
history. In outpatients, antibiotic therapy for UTI is usually started empirically and cultures are only performed if the
patient fails to respond to treatment, has recurrent episodes of UTI or has complicated UTI [18, 19]. Thus, data on
resistance rates based on laboratory surveillance may overestimate the true levels of antibiotic resistance in the
community, accounting for selection bias. However, since most urinary samples obtained at the Department of Urology
are sent for bacterial culture, the 22% resistance rate of E. coli to ciprofloxacin is likely to be a realistic number for the
population under study. Generalisation of these results may be restricted as these data were collected in a single hospital
department in one geographic area during an 18 months period. The odds ratios may be different in other settings, even
within Switzerland.
Risk factors for ciprofloxacin-resistant E. coli in UTIs have been presented by other authors [9–13]. The results of our
study are in agreement with risk factors previously reported, with prior exposure to fluoroquinolones being the most
commonly described factor to increase risk. Whereas other authors tried to find an association with the presence of a
urinary catheter at the time of detection of the ciprofloxacin-resistant strain [11, 12], we included prior urinary tract
catheterisation within one year as a possible risk factor. However, multivariable analysis did not reveal prior urinary tract
catheterisation as an independent risk factor. In contrast, Arslan et al. found an association between ciprofloxacin
resistance and complicated UTIs, including those patients with urinary catheters in situ [10]. Others have been able to
show a correlation between age (50 years and 65 years or older, respectively) and fluoroquinolone resistance [9–11],
whereas we could not. Differences between studies may have arisen due to different settings, different populations under
study, and, to some extent, disregard of collinearity and cocausality in multivariable analyses.
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During the study period, local guidelines of the University Hospital Zurich recommended a three day course of
norfloxacin or trimethoprim/sulfamethazol for the treatment of acute, uncomplicated UTI in young women, and a 5 day
course in men. Ciprofloxacin was only recommended as a first-line agent in the treatment of uncomplicated acute
pyelonephritis. The results of our study show that those recommendations were not followed properly, as ciprofloxacin
turned out to be the most frequently prescribed antibiotic for treatment of acute, uncomplicated UTIs. The fact that
ciprofloxacin is often given inappropriately is alarming. However, as there is no evidence that norfloxacin has a lower
capacity than ciprofloxacin to select for fluoroquinolone resistant strains, it cannot be assumed that following the
institutional guidelines would have resulted in a lower prevalence of fluoroquinolone resistant strains of E. coli. Naber et
al. demonstrated that most participants (microbiologists, infectious disease clinicians and clinicians with an interest in the
management of UTIs) underestimated fluoroquinolone use in the management of acute, uncomplicated lower UTI and
that they considered the high level of usage to be inappropriate from a societal perspective (risk of increased resistance)
[3]. This suggests that part of decreasing the usage of fluoroquinolones is to inform clinicians about their high
prescription rate as they tend to underestimate their use and are sometimes not aware of the high selection pressure. In
the study by Van Hees et al. about strategies to optimise the use of ciprofloxacin, it could be shown that the numbers of
inappropriate prescriptions can be reduced and the quality of prescriptions improved by educational interventions [20].
Similar investigations by Feucht et al. demonstrated that education of physicians resulted in an increase in appropriate
empiric antibiotic use, a decrease in duration of inappropriate use, and a decrease in duplicate gram-negative coverage
[21].
Across Europe, fluoroquinolone resistance rates show large differences, being generally high in southern Europe and
low in northern European countries [6, 7]. These geographical variations are also seen in antibiotic consumption [4, 6,
22], which is being recognised as the main cause of emerging resistance [11, 23, 24]. Those international differences
may be explained by different antimicrobial guidelines as well as cultural, demographic and socioeconomic factors, for
instance, over-the-counter sales or physicians’ and patients’ attitudes to antibiotics. In 2002, Switzerland was the country
with the lowest antibiotic consumption in the community in Europe. However, fluoroquinolones accounted for a share of
20.1% thereof, which is a much higher proportion compared to an average of 7.3% in the other European countries [25].
Although antibiotic consumption in our country is still considered to be low, continuous monitoring of resistance
development is essential to adapt guidelines for empirical antimicrobial therapy. In 2008, according to the SEARCH
database (Sentinel Surveillance of Antibiotic Resistance in Switzerland), the rate of non-susceptible E. coli to older
fluoroquinolones in urogenital infections of inpatients and outpatients aged ≥15 years reached 17.2% and 17.1%,
respectively [26].
To halt the process of resistance development, susceptibility testing to first-generation fluoroquinolones (e.g. nalidixic
acid) may be considered, as they indicate single mutation in the gyrA-gene whereof at least two are needed to provide
relevant resistance to later generation fluoroquinolones [27–29]. It has previously been suggested that selection pressure
could be reduced by refraining from fluorquinolone use when resistance to nalidixic acid is detected in order to decelerate
the accumulation of single mutations [11, 27, 29]. Nonetheless, resistance of E. coli is not only selected by the use of
fluoroquinolones, but also by the use of unrelated antimicrobial classes including ampicillin, amoxicillin, trimethoprim or
sulfamethoxazole alone, and trimethoprim-sulfamethoxazole [7]. Therefore, to decrease selection pressure to those
‘classic’ antibiotics, more frequent use of other antibiotics, for example nitrofurantion and fosfomycin, may be considered.
In complicated UTIs, microbiological testing is essential to ensure adequate therapy because of high resistance rates.
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